Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026)

Alkermes (ALKS) reported Total Non-Current Liabilities of $2.4 billion for Q1 2026, up 376.7% year-over-year from $511.5 million in Q1 2025, and up 301.93% quarter-over-quarter from $606.7 million in Q4 2025.

Alkermes (ALKS) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends

Alkermes (ALKS) has 16 years of Total Non-Current Liabilities data on file, last reported at $2.4 billion in Q1 2026.

  • Total Non-Current Liabilities for Q1 2026 came in at $2.4 billion, up 376.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 376.7% YoY), and the FY2025 annual result was $606.7 million, up 13.49% from the prior year.
  • Total Non-Current Liabilities advanced to $2.4 billion in Q1 2026 per ALKS's latest filing, from $606.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $2.4 billion in Q1 2026 and troughed at $511.5 million in Q1 2025.
  • A 5-year average of $859.5 million and a median of $856.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
  • The sharpest annual moves came in 2024 and 2026: Total Non-Current Liabilities tumbled 39.5% in 2024, then soared 376.7% in 2026.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $877.8 million in 2022, then climbed by 0.66% to $883.7 million in 2023, then plunged by 39.5% to $534.6 million in 2024, then increased by 13.49% to $606.7 million in 2025, then jumped by 301.93% to $2.4 billion in 2026.
  • Business Quant data shows ALKS's Total Non-Current Liabilities at $2.4 billion in Q1 2026, $606.7 million in Q4 2025, and $539.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Teva Pharmaceutical Industries 38.34 Bn 34.60 Bn 1.97 Bn 18.28 Bn
2 Zoetis 33.27 Bn 31.33 Bn 1.62 Bn 11.64 Bn
3 United Therapeutics 23.75 Bn 21.60 Bn 648.10 Mn 599.10 Mn
4 Aurora Cannabis 17.11 Bn 17.03 Bn 33.43 Mn 44.12 Mn
5 Neurocrine Biosciences 16.37 Bn 15.05 Bn 800.70 Mn 1.24 Bn
6 Elanco Animal Health 11.78 Bn 11.35 Bn 785.00 Mn 6.26 Bn
7 Alkermes 7.05 Bn 6.54 Bn -116.06 Mn 2.44 Bn
8 Lantheus Holdings 6.49 Bn 5.99 Bn 230.92 Mn 1.13 Bn
9 Hims & Hers Health 6.19 Bn 5.44 Bn 396.79 Mn 1.81 Bn
10 Liquidia 5.63 Bn 5.40 Bn 121.79 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 2.44 Bn
Dec 31, 2025 606.69 Mn
Sep 30, 2025 539.33 Mn
Jun 30, 2025 572.18 Mn
Mar 31, 2025 511.54 Mn
Dec 31, 2024 534.57 Mn
Sep 30, 2024 810.56 Mn
Jun 30, 2024 874.54 Mn
Mar 31, 2024 820.17 Mn
Dec 31, 2023 883.66 Mn
Sep 30, 2023 870.03 Mn
Jun 30, 2023 858.53 Mn
Mar 31, 2023 868.66 Mn
Dec 31, 2022 877.84 Mn
Sep 30, 2022 856.19 Mn
Jun 30, 2022 829.89 Mn
Mar 31, 2022 858.55 Mn
Dec 31, 2021 868.25 Mn
Sep 30, 2021 867.15 Mn
Jun 30, 2021 803.34 Mn